Market Place
Sourcing Support
Acumen Pharma to Participate in Stifel Healthcare Conference
11 Nov 2024 //
GLOBENEWSWIRE
Acumen Pharma Appoints Dr. Schacterle as CRO & Head of Quality
06 Nov 2024 //
GLOBENEWSWIRE
Acumen Pharma to Participate in UBS Global Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Acumen Pharma to Report Q3 Results on Nov. 12, 2024
05 Nov 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Presents pTau217 Assay Data at CTAD
31 Oct 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Late-Breaking Presentation at CTAD
23 Oct 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Joins Bank Of America CNS Conference
30 Sep 2024 //
GLOBENEWSWIRE
Acumen Pharma Extends Alzheimer’s Collaboration with Lonza
27 Sep 2024 //
CONTRACT PHARMA
Acumen Expand Alliance for Manufacture of Alzheimer’s Drug
26 Sep 2024 //
CONTRACTPHARMA
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
25 Sep 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Acumen Pharma Reports Q2 2024 Results And Business Highlights
13 Aug 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
06 Aug 2024 //
GLOBENEWSWIRE
Acumen Doses First Subject In Phase 1 Subcutaneous Sabirnetug Study
29 Jul 2024 //
GLOBENEWSWIRE
Acumen Shares Phase 1 INTERCEPT-AD Study Data At AAIC 2024
28 Jul 2024 //
GLOBENEWSWIRE
Acumen To Present INTERCEPT-AD Study Insights At AAIC® 2024
11 Jul 2024 //
GLOBENEWSWIRE
Acumen Pharma Reports Q1 2024 Results, Business Highlights
14 May 2024 //
GLOBENEWSWIRE
Acumen Pharma At HC Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Acumen First Patient Dosed In Alzheimer`s ALTITUDE-AD Trial
08 May 2024 //
GLOBENEWSWIRE
Acumen At 2024 BofA Healthcare Conference
08 May 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
06 May 2024 //
GLOBENEWSWIRE
Acumen Presents Sabirnetug (ACU193) Data at American Academy of Neurology 2024
16 Apr 2024 //
GLOBENEWSWIRE
Lonza, Acumen Pharmaceuticals Ink Alzheimer’s Alliance
04 Apr 2024 //
GLOBENEWSWIRE
Acumen Reports Financial Results for the Year Ended December 31, 23
26 Mar 2024 //
GLOBENEWSWIRE
Acumen to Present Sabirnetug (ACU193), During Session at the AAN Meeting
21 Mar 2024 //
GLOBENEWSWIRE
Acumen to Report Fourth Quarter & Year-End 2023 Financial Results
19 Mar 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
12 Mar 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker
08 Mar 2024 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker
21 Feb 2024 //
GLOBENEWSWIRE
Acumen Appoints Dr. James Doherty as President and Chief Development Officer
01 Feb 2024 //
GLOBENEWSWIRE
Acumen Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
GLOBENEWSWIRE
ValGenesis and Acumen Analytics Partner to Deploy Advanced Risk Management
07 Dec 2023 //
PR NEWSWIRE
Acumen Reports Third Quarter 2023 Financial Results and Business Highlights
13 Nov 2023 //
GLOBENEWSWIRE
Acumen Pharma Secures $50.0 Million Credit Facility with K2 HealthVentures
13 Nov 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration
06 Nov 2023 //
PR NEWSWIRE
Acumen Pharma to Report Third Quarter Financial Results on November 13, 2023
06 Nov 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
02 Nov 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates for ACU193
27 Oct 2023 //
GLOBENEWSWIRE
Acumen to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193
04 Oct 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
19 Sep 2023 //
GLOBENEWSWIRE
Acumen to Participate in the H.C. Wainwright Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Report Q2 Financial Results on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
Why Shares of Acumen Pharmaceuticals Are Down Tuesday
20 Jul 2023 //
FOOL
Acumen Announces Pricing of Upsized $130 Million Public Offering
18 Jul 2023 //
GLOBENEWSWIRE
Acumen to Hold Conference to Discuss Positive Results from Phase 1 of ACU193
17 Jul 2023 //
PRESS RELEASE
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
17 Jul 2023 //
GLOBENEWSWIRE
Acumen`s Alzheimer`s drug passes initial safety test
16 Jul 2023 //
REUTERS
Acumen to Present Topline Results from First-in-Human Phase 1 Study of ACU193
13 Jun 2023 //
PRESS RELEASE
Acumen Pharmaceuticals Reports1Q 2023 FYR and Business Highlights
09 May 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in 2023 Bank of America Conference
04 May 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
02 May 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Presents in vitro Human Neuron Model
28 Mar 2023 //
GLOBENEWSWIRE
Acumen Reports Financial Results for Full Year Ended December 31, 2022
27 Mar 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days
22 Mar 2023 //
GLOBENEWSWIRE
Acumen to Report Q4 and Year-End 2022 Financial Results on March 27, 2023
20 Mar 2023 //
GLOBENEWSWIRE
Acumen reveals late-stage clinical trial plans in early Alzheimer’s disease
28 Feb 2023 //
CLINICAL TRIALS ARENA
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193
13 Feb 2023 //
GLOBENEWSWIRE
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
04 Jan 2023 //
GLOBENEWSWIRE
